Every 10-Q that Sagimet Biosciences Inc. Series A (SGMT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow SGMT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SGMT filings page.
Sagimet Biosciences Inc. reported a net loss of $13.9 million for the quarter ended June 30, 2026, compared with $10.4 million a year earlier, as it advanced its fatty acid synthase (FASN) inhibitor pipeline. For the first six months of 2026, net loss was $24.6 million versus $28.6 million in 2025, reflecting lower year-to-date research and development spending.
Cash, cash equivalents and marketable securities totaled $257.6 million at June 30, 2026, up sharply from $116.5 million in total assets at year-end 2025, driven by an April 2026 underwritten offering of 29,166,700 Series A shares at $6.00 per share, providing $163.9 million in net proceeds. Total assets were $263.4 million and stockholders’ equity was $256.2 million, with minimal liabilities.
Management expects existing liquidity to fund operating expenses for at least 12 months. The company remains a clinical-stage biotech with no product revenue, focusing on lead candidate denifanstat for acne and MASH, and TVB-3567 in a Phase 1 acne trial, while MASH combination work will not move beyond Phase 2 readiness without non-dilutive funding.
Sagimet Biosciences Inc. reported a net loss of $10.7 million for the quarter ended March 31, 2026, an improvement from $18.2 million a year earlier. The smaller loss was driven by a 54% drop in research and development expense to $7.0 million as Phase 3 MASH work wound down and spending shifted toward acne programs.
General and administrative costs were stable at $4.7 million, while other income declined to $1.1 million due to lower cash balances and yields. Sagimet ended the quarter with $104.5 million in cash, cash equivalents and marketable securities and then raised about $175.0 million in an April 2026 underwritten offering, which it expects to fund operations for at least 12 months.
The company continues to advance FASN inhibitor programs: denifanstat, which met Phase 3 acne endpoints in China through its partner Ascletis, is planned to enter a U.S. Phase 3 acne trial after an IND filing in mid-2026, and TVB-3567 is in a Phase 1 acne study. Further MASH development will pause until non-dilutive financing is secured.
Sagimet Biosciences (SGMT) reported Q3 2025 results showing a net loss of $12.9 million as it advances its fatty acid synthase inhibitor programs. Operating expenses were $14.3 million, with research and development of $9.7 million, down 23% year over year on lower Phase 3 denifanstat clinical costs, partly offset by a $2.5 million up-front CMO license fee and new early‑stage studies. General and administrative expenses were $4.6 million.
Liquidity remained solid with cash, cash equivalents and marketable securities of $125.5 million as of September 30, 2025, and management expects this to fund operations for at least the next 12 months. The company established a $75.0 million at‑the‑market program in August 2025 with no sales in the quarter. Accumulated deficit was $336.8 million.
Program updates: denifanstat met primary and multiple secondary endpoints in Phase 2b MASH and a Phase 1 PK trial combining denifanstat with resmetirom began in September 2025. In acne, Sagimet’s partner reported Phase 3 success in China and plans an NDA submission. Sagimet also began a Phase 1 trial of TVB‑3567 for acne in June 2025.
Sagimet Biosciences (SGMT) is a clinical-stage biopharmaceutical company developing FASN inhibitors led by denifanstat. The company reported strong clinical progress: its Phase 2b FASCINATE-2 trial in MASH achieved both primary endpoints with statistically significant histologic and biomarker improvements, and denifanstat received FDA Breakthrough Therapy designation for non-cirrhotic MASH with F2-F3 fibrosis. License partner Ascletis reported denifanstat met all primary and secondary endpoints in a Phase 3 acne trial and plans submission in China.
Financially, Sagimet had $135.5 million of cash, cash equivalents and marketable securities as of June 30, 2025 and expects these funds to support operations for at least 12 months. R&D spend rose sharply as programs advanced: six-month R&D expense was $22.59 million (up 95% year-over-year). Net loss for six months was $28.56 million, and the company had an accumulated deficit of $323.9 million. TVB-3567 received IND clearance in March 2025 and a first-in-human Phase 1 trial began in June 2025.